AEZS Aeterna Zentaris Inc.

1.14
0  0%
Previous Close 1.14
Open 1.16
Price To Book -12.67
Market Cap 26,758,959
Shares 20,031,610
Volume 30,943
Short Ratio
Av. Daily Volume 427,502
Stock charts supplied by TradingView

NewsSee all news

  1. Aeterna Zentaris Announces Results of 2020 Annual Meeting of Shareholders

    CHARLESTON, S.C., May 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and

  2. Aeterna Zentaris Announces Virtual 2020 Annual Meeting of Shareholders

    CHARLESTON, S.C., May 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and

  3. Aeterna Zentaris Reports First Quarter 2020 Financial and Operating Results

    – First quarter marked by positive results from AEZS-130-P01 ("Study P01"), of macimorelin, providing clinical framework to advance pediatric investigation plan ("PIP") for macimorelin as a growth hormone deficiency

  4. Aeterna Zentaris Receives Nasdaq Notice of Non-Compliance; No Immediate Impact on Listing

    CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna Zentaris" or the "Company"), a specialty biopharmaceutical company commercializing and developing

  5. Aeterna Zentaris to Present at the April 2020 Virtual Investor Summit

    CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna Zentaris" or the "Company"), a specialty biopharmaceutical company commercializing and developing

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
Phase 3 trial did not meet primary endpoint - May 1, 2017.
Zoptrex
Endometrial cancer

Latest News

  1. Aeterna Zentaris Announces Results of 2020 Annual Meeting of Shareholders

    CHARLESTON, S.C., May 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and

  2. Aeterna Zentaris Announces Virtual 2020 Annual Meeting of Shareholders

    CHARLESTON, S.C., May 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company commercializing and developing therapeutics and

  3. Aeterna Zentaris Reports First Quarter 2020 Financial and Operating Results

    – First quarter marked by positive results from AEZS-130-P01 ("Study P01"), of macimorelin, providing clinical framework to advance pediatric investigation plan ("PIP") for macimorelin as a growth hormone deficiency

  4. Aeterna Zentaris Receives Nasdaq Notice of Non-Compliance; No Immediate Impact on Listing

    CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna Zentaris" or the "Company"), a specialty biopharmaceutical company commercializing and developing

  5. Aeterna Zentaris to Present at the April 2020 Virtual Investor Summit

    CHARLESTON, S.C., April 15, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna Zentaris" or the "Company"), a specialty biopharmaceutical company commercializing and developing

  6. JTC Team and LaVoieHealthScience to Host Virtual Investor Summit on April 22 and 23, 2020

    Access the event and schedule of presenting companies at virtualinvestorsummit.com Live audio webcast presentations and interactive Q&A Company presentations will be held from 10 AM-12 PM ET and 1 PM-3 PM ET on

  7. AETERNA ZENTARIS ANNOUNCES EMA DECISION TO ACCEPT A MODIFICATION TO AN AGREED PEDIATRIC INVESTIGATION PLAN FOR MACIMORELIN

  8. AETERNA ZENTARIS ANNOUNCES POSITIVE RESULTS IN DOSE-FINDING PEDIATRIC STUDY OF MACIMORELIN

    – Positive results provide clinical framework to advance the Company's Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic – – Pediatric PK/PD profile of macimorelin proved to be in

  9. AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

    – Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ – – Robust ongoing business development discussions to secure a commercialization

  10. Aeterna Zentaris to Present at Noble Capital Markets' 16th Annual Investor Conference

    CHARLESTON, S.C., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), specialty biopharmaceutical company commercializing and developing therapeutics and

  11. Aeterna Zentaris Announces Completion of Patient Recruitment in Dose-Finding Pediatric Study of Macimorelin

    – Study P01 is the first of two studies as agreed with the EMA in the Company's Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic – – Study P01 final study results expected in Q2

  12. Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing

    CHARLESTON, S.C., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical

  13. Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer

    CHARLESTON, S.C., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) today announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company, effective